LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION

Autor:	I. I. Kopchenov, Olga D. Ostroumova, M. L. Maksimov
Rok vydání:	2013
Předmět:	lcsh:Diseases of the circulatory (Cardiovascular) system arterial hypertension medicine.drug_class лерканидипин RM1-950 Calcium channel blocker Pharmacology антагонисты кальция law.invention антигипертензивная терапия calcium antagonists law medicine Diseases of the circulatory (Cardiovascular) system Pharmacology (medical) antihypertensive therapy Clinical pharmacology business.industry Calcium channel Lercanidipine lcsh:RM1-950 lercanidipine Dihydropyridine артериальная гипертензия Third generation lcsh:Therapeutics. Pharmacology lcsh:RC666-701 RC666-701 Therapeutics. Pharmacology Cardiology and Cardiovascular Medicine business medicine.drug
Zdroj:	Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 9, Iss 1, Pp 79-85 (2015)
ISSN:	2225-3653 1819-6446
DOI:	10.20996/1819-6446-2013-9-1-79-85
Popis:	Classification, modes of action and clinical effects of calcium channel blockers are presented. Advantages of the third generation of dihydropyridine calcium channel blockers are considered. Clinical pharmacology, studies on the efficacy, safety and prevention of hypertensive complications with lercanidipine are detailed.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6b740b8c7d07362cc086f39c6ee1335 https://doi.org/10.20996/1819-6446-2013-9-1-79-85 Zobrazit plný text záznamu